Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Nature BioTech SciCafe

Summary

Related Content

FDA Proposes Phased Approach to Regulating Laboratory Developed Tests

Regulatory Update on Alvotech’s AVT02, a High-Concentration Interchangeable Adalimumab Biosimilar

FDA Grants Priority Review to Merck’s Application for KEYTRUDA (pembrolizumab) as Part of Treatment for Early-Stage Cervical Cancer

FDA Proposes Phased Approach to Regulating Laboratory Developed Tests

A Look Ahead in Life Sciences: What We Are Tracking in Q4 2023 and Beyond

Recent Biosimilar Commercialization Developments

Bloomberg Intelligence – Arman Oruc’s Perspective on the FTC and Pharma and Biotech Industry M&A Impact

Scheduling Order Issued in REGENXBIO v. Sarepta Litigation

Goodwin Names 40 New Partners

Matt Wetzel Named the 2023 Patricia T. Meador Leadership Award Recipient by the American Health Law Association

Goodwin Expands Life Sciences Practice with Capital Markets Partner Adam Johnson in New York

FemHealth Ventures Closes $32 Million Fund for Women’s Health Investments (The Wall Street Journal)

Acino Significantly Expands Presence and Capabilities in Latin America Through Acquisition of M8 Pharmaceuticals

Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year

Aditum Bio Announces Formation of Celexor Bio, Focused on Cell Depletion of Pathologic Cells in Autoimmune and Inflammatory Disorders

Orionis Biosciences Announces Collaboration with Genentech to Discover and Develop Molecular Glue Class Medicines

Life Sciences